Weekly cisplatin/low-dose gemcitabine combination for advanced and recurrent cervical carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 2, 2001, Pages 201-203

  Dueñas Gonzalez, Alfonso ^a,b   Hinojosa García, Luz María ^a,b   López Graniel, Carlos ^a,b   Meléndez Zagla, Jorge ^a,b   Maldonado, Vilma ^a,b   De La Garza, Jaime ^a,b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Advanced; Cervical carcinoma; Cisplatin; Gemcitabine; Recurrent

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; GEMCITABINE; MANNITOL; ONDANSETRON;

ADULT; ALOPECIA; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; GYNECOLOGIC CANCER; HUMAN; RECURRENT CANCER; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 0035052827     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200104000-00020     Document Type: Article

References (5)

1. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A Gynecology Oncology Group Study
2. Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study
3. An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II
4. A phase II study of gemcitabine in advanced cervix carcinoma: Final data
5. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix